The 133 patients for whom both PD-L1 and CD8 expression data were available were stratified into four TME groups on the basis of cutoffs of 1% for PD-L1 combined positive score (CPS) and of the median (85/mm2) for CD8+ tumor-infiltrating lymphocyte (TIL) density (Fig. 1A). The gene discussed is CD274; the disease is neoplasm.